All Releases
 |
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Feb 21, 2012
|
20.1 KB |
|
| |
HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011.
Financial Results:
Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the sa...
|
|
Anthera Announces Fourth Quarter 2011 Financial Report and Conference Call
Feb 9, 2012
|
10.0 KB |
|
| |
HAYWARD, Calif., Feb. 9, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, will release its fourth quarter 2011 financial report before the market opens on Tuesday, February 21, 2012. Anthera will host a conference call at 1 pm East...
|
|
Anthera Announces Completion of Safety Review by DSMB for VISTA-16
Dec 14, 2011
|
11.5 KB |
|
| |
HAYWARD, Calif., Dec. 14, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that the VISTA-16 Data Safety Monitoring Board (DSMB) has met for the fifth time to review available safety data an...
|
|
Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
Dec 5, 2011
|
11.4 KB |
|
| |
HAYWARD, Calif., Dec. 5, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders, today announced Dr. Debra Odink has been promoted to the role of Chief Technology Officer and Senior Vice President.
...
|
|
Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEARL-SC Study
Dec 1, 2011
|
13.2 KB |
|
| |
HAYWARD, Calif., Dec. 1, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.
After analysis by...
|
|
Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
Nov 1, 2011
|
20.1 KB |
|
| |
HAYWARD, Calif., Nov. 1, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter ended September 30, 2011.
Financial Results:
Total operating expenses for the third quarter ended September 30, 2011 were $23.4 million, as compared to $8.4 million for the sam...
|
|
Anthera Announces Last Patient Enrolled in PEARL-SC Study
Oct 25, 2011
|
13.8 KB |
|
| |
HAYWARD, Calif., Oct. 25, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has completed enrollment in the Phase 2b PEARL-SC study. PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, s...
|
|
Anthera Announces Third Quarter 2011 Financial Report and Conference Call
Oct 24, 2011
|
10.0 KB |
|
| |
HAYWARD, Calif., Oct. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2011 financial report and provide an update on its development programs after market close on Tuesday, Nov...
|
|
Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
Sep 8, 2011
|
12.5 KB |
|
| |
HAYWARD, Calif., Sept. 8, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that the U.S. Patent and Trademark Office has given the Company a Notice of Allowance for U.S. Patent Application No. 12/114,710 entitled "T...
|
|
Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
Jul 29, 2011
|
18.9 KB |
|
| |
HAYWARD, Calif., July 29, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter ended June 30, 2011.
Financial Results:
Total operating expenses for the second quarter ended June 30, 2011 were $22.7 million, as compared to $7.9 million for the same period...
|
|
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
Jun 8, 2011
|
12.1 KB |
|
| |
HAYWARD, Calif., June 8, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 6,666,667 shares of its common stock, offered at a price of $7.50 per share. In addition, the Company has sold 1,000,000 shares of its common stock at a price of ...
|
|
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Jun 3, 2011
|
12.3 KB |
|
| |
HAYWARD, Calif., June 3, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock, offered at a price of $7.50 per share. The offering is expected to close on or about June 8, 2011, subject to customary closing conditions. In addition, An...
|
|
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jun 2, 2011
|
12.0 KB |
|
| |
HAYWARD, Calif., June 2, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the p...
|
|
Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
May 3, 2011
|
18.6 KB |
|
| |
HAYWARD, Calif., May 3, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter ended March 31, 2011.
Financial Results:
Total operating expenses for the first quarter ended March 31, 2011 were $18.7 million, as compared to $6.5 million for the same period ...
|
|
Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
Apr 18, 2011
|
14.9 KB |
|
| |
HAYWARD, Calif., April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that enrollment in the Phase 3 VISTA-16 study of varespladib in Acute Coronary Syndromes (ACS) will continue based on the positive outcome ...
|
|
Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Feb 24, 2011
|
9.9 KB |
|
| |
HAYWARD, Calif., Feb. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced Paul Truex, Anthera's President and Chief Executive Officer, will present at Citi's 2011 Global Health Ca...
|
|
Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
Feb 23, 2011
|
10.6 KB |
|
| |
HAYWARD, Calif., Feb. 23, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to discuss the analytical method of the upcoming VISTA-16 interim biomarker analysis and the expected timelin...
|
|
Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
Feb 23, 2011
|
20.5 KB |
|
| |
HAYWARD, Calif., Feb. 23, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter and year ended December 31, 2010.
Financial Results
Total operating expenses for the fourth quarter ended December 31, 2010, were $12.9 million, as compared to $1.4 million fo...
|
|
Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
Feb 8, 2011
|
12.0 KB |
|
| |
HAYWARD, Calif., Feb. 8, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced that it has appointed Lawrence Rosania to the position of Vice President of Global Regulatory Affairs and ...
|
|
Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
Feb 1, 2011
|
11.4 KB |
|
| |
HAYWARD, Calif., Feb. 1, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced that it has appointed Dr. Peter Thompson to its Board of Directors. Currently, Dr. Thompson is a venture p...
|
|
|
